Republic of Botswana - Admin
Republic of Botswana - Admin
Republic of Botswana - Admin
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
8. Consumer:<br />
A person who is not a Health Care Pr<strong>of</strong>essional such as a patient, lawyer, friend<br />
orrelative / parents/ children <strong>of</strong> a patient.<br />
9. Health care pr<strong>of</strong>essional:<br />
Defined as medically qualified persons, such as medical practioners,<br />
pathologists, dentists, pharmacists’ nurses, coroners, veterinarians and paraveterinary<br />
pr<strong>of</strong>essionals including veterinary nurses and animal health<br />
technicians.<br />
10. Pharmacovigilance: Pharmacovigilance is concerned with the detection, assessment,<br />
prevention <strong>of</strong> adverse reactions <strong>of</strong> drugs and any drug related problems.<br />
11. Drug/Medicine Interactions<br />
Any drug interaction, which results in an adverse reaction, should be reported as<br />
an adverse reaction in the prescribed manner.<br />
12. ADR Case Report : A notification relating to a patient with an adverse medical event (or<br />
laboratory test abnormality) suspected to be induced by a medicine.<br />
13. Lack <strong>of</strong> Efficiency: Defined as a failure to produce the expected pharmacological action.<br />
III. Rationale <strong>of</strong> ADR monitoring<br />
Reporting ADR is essential to obtain the necessary information on safety<br />
<strong>of</strong> different subgroups such as children, pregnant women, elderly and patients with complicated<br />
disease or multiple conditions, which are not normally exposed during the clinical trial.<br />
It is also essential for the early detection <strong>of</strong> unknown reactions and interactions between<br />
medicines, detection <strong>of</strong> increase in ADR frequency, identification and quantification <strong>of</strong> risk<br />
factors, detection and removal <strong>of</strong> counterfeited and substandard drugs in the market.<br />
IV. PHARMACOVIGILANCE:<br />
5